How GLP-1 Drugs Work—and Why They Do So Much
GLP-1 receptor agonists like semaglutide mimic a natural gut hormone to control blood sugar and appetite, but emerging research shows they also protect the heart, kidneys, and possibly even joints.
A Gut Hormone With Outsized Power
Every time you eat, specialized cells lining your small intestine release a hormone called glucagon-like peptide-1, or GLP-1. This molecule belongs to a family known as incretins—hormones that tell the pancreas to produce insulin when blood sugar rises after a meal. In a healthy body, natural GLP-1 does its job and is broken down within minutes by an enzyme called DPP-4.
That fleeting lifespan made GLP-1 an unlikely drug candidate. But pharmaceutical scientists figured out how to engineer synthetic versions that resist DPP-4 and last for hours—or even a full week. The result is a class of medications called GLP-1 receptor agonists, including semaglutide (marketed as Ozempic and Wegovy), tirzepatide (Mounjaro and Zepbound), and liraglutide (Victoza and Saxenda). Originally developed for type 2 diabetes, these drugs have become the most talked-about medications in modern medicine.
How GLP-1 Receptor Agonists Work
GLP-1 drugs operate on multiple fronts simultaneously. In the pancreas, they boost insulin secretion in a glucose-dependent manner—meaning they help lower blood sugar only when it is elevated, reducing the risk of dangerous hypoglycemia. They also suppress glucagon, a hormone that raises blood sugar.
In the gut, these drugs slow gastric emptying, keeping food in the stomach longer. This extends feelings of fullness and reduces the urge to eat again quickly.
But perhaps the most powerful effects occur in the brain. GLP-1 receptors are found in the hypothalamus and brainstem—regions that regulate appetite and reward. The drugs stimulate neurons that promote satiety (POMC/CART neurons) while inhibiting those that drive hunger (NPY/AgRP neurons). According to a 2025 review in The American Journal of Medicine, the weight-loss effect comes predominantly from reduced energy intake rather than increased calorie burning.
Beyond Blood Sugar and Body Weight
What has surprised researchers most is how far GLP-1 drugs reach beyond their original purpose. A growing body of evidence points to significant cardiovascular benefits. Meta-analyses published in The Lancet show GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events—heart attack, stroke, and cardiovascular death—by approximately 13% in patients with type 2 diabetes. They also cut kidney failure risk by 16%.
The New England Journal of Medicine reported that semaglutide reduced major kidney events by 24% in patients with chronic kidney disease and diabetes, establishing these drugs as potential kidney protectors as well.
The latest frontier is joint health. In April 2026, researchers at Aarhus University Hospital in Denmark discovered that the body's natural GLP-1 is present in synovial fluid—the lubricant inside joints. Published in The Lancet Rheumatology, the finding suggests GLP-1 drugs might directly reach and act within joints. Preclinical studies have already revealed anti-inflammatory and cartilage-protecting properties independent of weight loss, and phase 3 trials of both semaglutide and retatrutide in knee osteoarthritis have shown significant pain reduction.
How the Body Makes Its Own GLP-1
Understanding natural GLP-1 helps explain why these drugs are so versatile. The hormone is produced mainly by L-cells concentrated in the ileum and colon. Meals rich in fiber, protein, and healthy fats stimulate its release. Soluble fiber is particularly effective: gut bacteria ferment it into short-chain fatty acids, which in turn trigger L-cells to secrete more GLP-1.
This biology has led some researchers to investigate whether dietary changes—more fiber, fermented foods, and slower eating—can meaningfully boost natural GLP-1 levels, though no diet comes close to replicating the effect of pharmaceutical doses.
What Comes Next
The GLP-1 drug class is expanding rapidly. Dual and triple agonists that target GLP-1 alongside related receptors (GIP and glucagon) are entering the market, promising greater efficacy with fewer side effects. Researchers are investigating GLP-1 drugs for conditions as varied as Alzheimer's disease, addiction, and liver fibrosis.
Side effects—primarily nausea, vomiting, and gastrointestinal discomfort—remain a concern, and long-term safety data is still accumulating. But for a hormone that the body destroys in two minutes, GLP-1 has proven remarkably durable as a therapeutic target.
